Guest guest Posted December 24, 2010 Report Posted December 24, 2010 Bringing the Heat: An ME/CFS (Chronic Fatigue Syndrome) Blog From Phoenix Rising Phoenix Rising and Rising….PR Is Official! The Stanford Initiative For Chronic Infectious Diseases (including ME/CFS) XMRV Buzz: Racaniello Retracts/ Jumps In/Retrovirologist `Superteam' To Form Rebuttal/Annette, Judy on Nevada Newsmakers XMRV Buzz (Dec 21st): The Retrovirology Papers Day II Phoenix Rising and Rising….PR Is Official! Posted: 23 Dec 2010 09:10 PM PST Phoenix Rising is an officially designated 501 3C non-profit which means that donations are tax deductable, and, of course, we'd love to take some off your hands Phoenix Rising is currently engaged in several exciting projects; two treatment and physician review projects to help patients better determine which treatments to take and which doctors to see, an large online survey to gather data on the types of CFS and a website overhaul. We are a small but vital organization that aims to make a difference. Please Donate! Related posts: Chronic Fatigue Syndrome ME/CFS News From Phoenix Rising – Make the Turnips Dance – Raise Money for Phoenix Rising! Make the Turnips Dance – Raise Money for Phoenix Rising!... Christmas Shopping For Phoenix Rising Shopping! The easy way to support Phoenix Rising as it... The Phoenix Rising Video Teejkay has done an amazing job on this poignant video... Related posts brought to you by Yet Another Related Posts Plugin. The Stanford Initiative For Chronic Infectious Diseases (including ME/CFS) Posted: 23 Dec 2010 02:04 PM PST Dr. Montoya runs the Infectious Disease Clinic at Stanford University. His 50 plus publications have focused on wide range of pathogens including toxoplasma, encephalomyelitis, herpesvirus 6, cytomegalovirus, acanthoamoeba, and many more etc. A preliminary study several years ago suggesting that antiviral therapy returned a large percentage of the recipients to health sent a jolt through the ME/CFS Community. A followup study will soon be released. He recently sent a letter to his patients and supporters that caught them up to date on his work and his plans for chronic fatigue syndrome and other chronic inflammatory infectious disorders. He is another example of a respected researcher that has made a strong commitment to chronic fatigue syndrome – something we can all be grateful for. If he's successful at what he's attempting to do he'll achieve one of the great goals of ME/CFS research; he'll define a group or groups of patients using biomarkers giving them legitimacy and providing them treatments and shepherding them into the embrace of the US medical system. Of course he'll be doing that under the umbrella of one of the more prestigious Universities in the world. Below is an overview of the letter; the entire letter is posted below Dr. Montoya is leading the august Stanford University into areas where many other university's fear to tread – the chronic infectious diseases such Lyme Disease, (some types of) ME/CFS as well as multiple sclerosis (MS). It appears, though, that his initial work has paid off and has laid the groundwork for growth in the future. Dr. Montoya reports that he has been able to identify several subgroups of patients who's lives have been `dramatically changed' due to prolonged anti-microbial (antiviral/antibacterial) therapy. His new initiative aims to investigate the infectious underpinnings of, and provide biomarkers for,a wide array of difficult to understand diseases including ME/CFS, chronic Lyme disease, epilepsy, MS and others. Recent work - they have recently wrapped up a number of longstanding projects and have or are submitting the results for publication. These include two papers on the double-blinded Valganciclovir trials in EBV and HHV-6 positive ME/CFS patients that started some years ago. Another paper indicating both that clinical (symptoms) and viral titers responded to antiviral treatment in HHV-6 infected patients should be in press in the not too distant future. (Interlude: Barcelona Conference - According to a report on the internet http://pochoams.blogspot.com/2010/11…-november.html in November Dr. Montoya presented evidence suggesting that monocytes may key a role in this type of ME/CFS patient and that several immune markers (IL5, IL17F, ENA78, EOTAXIN, IP10) improved during treatment – a potential breakthrough in demonstrating the legitimacy of antiviral treatment (and the disorder itself). He has also found that an early antigen marker usually associated with cancer may be a biomarker for this group, that HHV6 integrates into the chromosome of CFS patients, which is apparently not normal for this virus. (Viral integration into the chromosomes means that when the cell replicates the virus replicates as well). Current Work: The Big Pathogen Study – They are currently collaborating with Dr. Lipkin and other colleagues on a comprehensive analysis of the pathogens in ME/CFS Immune Signatures - They are analyzing the immune response using gene expression, cytokine profiles and phosph immune-flow to look for biomarkers and immune signatures correlated with these infections. These biomarkers could be used both to diagnose and to assess improvements during treatment. Biomarkers in the Brain – Finally? – in a novel approach that reminds one of the attempts to correlated MRI findings with disease early on in the history of CFS, the Montoya team is doing sophisticated new MRI techniques to see if they can use brain imagining to identify unique abnormalities in infected individuals. Several of these pathogens are able to access the central nervous system. A New Website - a new website explaining their work should be open early next year and a patient forum has been set up. Quantifying Impairment -Legitimizing ME/CFS - they are also using sub-maximal exercise testing and EEG readings to quantify (and make real) the physical and cognitive impairments in ME/CFS. Education and Outreach A Major Research Meeting – will be held to change information on and educate investigators on `chronic inflammatory diseases. Biennial Education Meeting – will educate researchers, students, etc. on their progress The Ultimate Goal - is the formation of a Center for Infection Induced Chronic Disease at Stanford, kind of a Stanford Centers Of Excellence for chronic infectious diseases that combines treatment and research. This is a big project that takes much teamwork and over the next five years Dr. Montoya has committed to enrolling and integrating many of Stanford's best faculty and resources in the project and already has the support of the Director of the Institute for Immunity, Transplantation and Infection, and the Chair of the Department of Medicine. If you would like more information about any of the projects listed, are interested in participating in any of the research, or would like to financially support a project please contact June Lang at 650-234-0674. Let the good times roll… STANFORD UNIVERSITY MEDICAL CENTER STANFORD UNIVERSITY SCHOOL OF MEDICINEDEPARTMENT OF MEDICINEDIVISION OF INFECTIOUS DISEASES & GEOGRAPHIC MEDICINE TELEPHOl\1E: 650/853-4824FAX: 650/329-9853WEBSITE: www.pamf.orglserologyDIVISION OF INFECTIOUS DISEASES & GEOGRAPHIC MEDICIl\1E300 PASTEUR DRIVE, MlC 5107STANFORD, CA94301NEWS FROM THE STANFORD INITIATIVE FOR THESTUDY OF INFECTION-ASSOCIATED CHRONIC DISEASES FALL / WINTER 2010 Stanford University is taking the lead in a critical area where research is lacking: the study of patients with unexplained chronic illnesses. Chronic Lyme disease (CLD), chronic fatigue syndrome (CFS), and multiple sclerosis (MS) for example, can significantly impair the lives of our patients and result in substantial reductions in previous levels of occupational, educational, social, or personal activities. Our group has taken a broad-spectrum, innovative approach to discovery surrounding these debilitating diseases. Five years ago our team postulated that infection, or the body's immune response to it, can play an etiologic role in CLD, CFS and MS. We also hypothesized that prolonged and specific antimicrobial interventions could result in partial or complete reversal of a patient's symptoms. Since then, we have been able to successfully identify several subgroups of patients whose lives have been dramatically changed with our approach [Kogelnik, 2006]. Our hypothesis has been reinvigorated by the publication last year on the possible association of a relatively unknown infectious agent, namely the Xenotropic murine leukemia virus-related virus (XMRV) [Lombardi, 2009] and the subsequent studies on this virus. Our proposed initiative for infection-associated chronic diseases will be focusing on chronic Lyme disease, chronic fatigue syndrome, epilepsy, multiple sclerosis, and other unexplained chronic illnesses. We are interested in learning more about the infectious agents that may play an etiologic role in these diseases, including human herpesvirus-6 (HHV-6), retroviruses such as the Xenotropcic murine leukemia virus-related virus (XMRV), parasites such as Toxoplasma gondii, fungi such as Coccidiodes immitis, and bacterial infections such as Borrelia burgdoferi (Lyme). We hope to see our work changing the lives of patients suffering from CLD and CFS. Our aim is to see patients being validated by their health care providers and fully integrated back into mainstream medicine. We plan to identify biomarkers and other tests that can be diagnostic for these diseases so that appropriate and personalized treatments can finally take place and end individual suffering. TO DATE WE HAVE MADE PROGRESS IN THE FOLLOWING AREAS: Completed Research:• Last year we completed a randomized, double-blind, placebo-controlled trial on the use of Valganciclovir in patients with chronic fatigue syndrome (CFS)and elevated human herpes virus-6 (HHV-6) and Epstein-Barr Virus(EBV) antibodies. Results from this study are presently being written up and a manuscript will be submitted for publication in December 2010.• This summer we completed a manuscript using observational data on the response to valganciclovir treatment in Chronic Fatigue Syndrome patients with positive Human Herpes virus 6 and Epstein-Barr virus IgG titers. We are submitting it for publication this month.• We are also in the process of submitting a manuscript showing that antiviral therapy induces viral and clinical response in patients with central nervous system dysfunction andchromosomally integrated Human Herpes virus 6. Dissemination of CFS research: Our team frequently presents research findings at national and international meetings. Sharing Stanford's perspective on pathogens in chronic illness and talking with other physicians who share our interest is important in advancing knowledge and treatment in the entire field of infectious disease. Formation of an online patient's support forum: A support forum has been set up on so Stanford's CFS patients may interact and give support to each other. WE ARE CONTINUING OUR IMPORTANT WORK IN THE FOLLOWING AREAS: Detection of infectious pathogens that may be a trigger for chronic diseases: We are looking for pathogens such as herpes viruses, the Lyme disease agent, xenotropic murine leukemia virus-related virus (XMRV), Toxoplasma gondii, or any unknown pathogen that may be a trigger for chronic diseases such as CFS(chronic fatigue syndrome), CLD (chronic Lyme disease) or other diseases. We plan to lookfor such pathogens in a broad population of CFS patients at Stanford and compare the findings to age and sex-matched controls. Towards this end we are collaborating with: Manisha Desai, Ph.D, Clinical Associate Professor of MedicineHolden Maecker, Ph.D, Director, Human Immune Monitoring Core, here at Stanford;and my colleagues at the Columbia University Medical Center in New York City:W. Ian Lipkin, MD, The Snow Professor of Epidemiology, and Director,Center for Infection & Immunity, Professor of Neurology and PathologyMady Hornig, MA, MD, Associate Professor of Epidemiology. Investigation of gene expression and immune system dynamics of infection in acute and chronic diseases: Our team is working on new studies to understand the immune response and possible immune dysfunction observed in our patients. We are looking at gene expression, cytokine profiles, and phospho immunoflow to learn whether our patients' immune response correlates with the presence of an infectious agent, organism, or pathogen. We hope to identify new markers from the blood that may help predict changes in disease over time and response to changes in medication. Towards these goals we are collaborating closely with the Human Immune Monitoring Core facility at Stanford, including Mark , Ph.D, Professor of Medicine in the Division of Microbiology and Immunology, and Holden Maecker, Ph.D. Discovery of possible biomarkers in the brain of infection-associated CFS patients: We are collaborating with the Neuroradiology department at Stanford to investigate the rol of novel magnetic resonance imaging (MRI) techniques (e.g. using a 3T magnet) in the hope of discovering biomarkers in the brain for infection-associated CFS.These MRI tests are not available for routine clinical use at this time. Atlas, MD, Professor of Medicine in the Division of Radiology, and his neuroradiology fellows are helping us analyze preliminary imaging data to apply for an NIH grant to begin a larger study on neuroimaging in CFSpatients. Creation of a Stanford Chronic Fatigue Initiative website: We have been working hard (many thanks to Lindsey Merrihew) to set up a website that will provide patients and their providers with information on Infection Associated Chronic Illnesses. The website should be operational by January. This website should be operational sometime in January. There will be a different web address than the one listed here. We will let you know when that website is operational. PROJECTS: Establishment of objective parameters to guantify the physical and cognitive impairments experienced by our patients: Francois Haddad, MD, clinical assistant professor of medicine in the division of cardiovascular medicine, is working with our patients using a sub-maximal effort exercise testing machine to find an objective method to assess fatigue and physical impairment. Marcie Zinn, Ph.D, anexperienced neuropsychologist, will be working with neuropsychological testing and an EEGmachine to find an objective method to quantify cognitive dysfunction in our patients. Lack of these objective parameters is partially responsible for the skepticism widely prevalent in the medical community towards these patients. We hope that our efforts will result in validated tests that will improve our capacity to diagnose physical and cognitive impairment as well as to evaluate treatment interventions. Educational outreach: We will host a major research meeting with the participation of international investigators to increase the understanding and the exchange of information in the field of chronic inflammatory disease. A biennial educational meeting aimed at practicing physicians, fellows, residents, and medical students will be initiated. We believe that we can significantly impact the field by reeducating the nascent and established medical community about the major and complex issues faced by our patients. DREAM PROJECTS: Formation ofa Center for Infection Induced Chronic Disease at Stanford: We hope, with your financial support, to establish an inpatient center separate from a hospital environment where patients with chronic diseases can benefit from a holistic approach to their treatment. Patients will receive treatment for the specific infectious agents likely to be playing a role in their disease over the course of weeks to months. In addition, they will receive complementary treatments to promote recovery and healing. MOVING FORWARD: During the next five years we will mobilize and integrate many of Stanford's best faculty and resources toward our mission and goals. The director of the Institute for Immunity, Transplantation and Infection, and the Chair of the Department of Medicine have committed to support our mission and have been an integral and key part in the development of this initiative. The task ahead of us is monumental and requires the participation of faculty and researchers from many areas. Under the leadership of the principal investigator, G. Montoya, MD, we have already begun assembling a world-class team of researchers, post-doctoral fellows, statisticians, bioinformatics faculty, graduate students, laboratory personnel (human immune monitoring core facility), a neuropsychologist, and an exercise physiologist. If you would like more information about any of the projects listed, are interested in participating in any of the research, or would like to financially support a project please contact June Lang at 650-234-0674. Relocation of the CFSclinic: The CFSclinic has moved to a new location. Please note that the new address is 900 Blake Wilbur Drive, Palo Alto, CA 94304. Once you are on Pasteur Drive, turn left on Blake Wilbur Drive. The clinic will be on the left, and parking is available in the parking garageon the right. The CFSclinic is located on the second floor. For directions see: http://stanfordhospital.org/directions/maps/BW.html No related posts. Related posts brought to you by Yet Another Related Posts Plugin. XMRV Buzz: Racaniello Retracts/ Jumps In/Retrovirologist `Superteam' To Form Rebuttal/Annette, Judy on Nevada Newsmakers Posted: 23 Dec 2010 01:25 PM PST Dr. Racaniello Retracts Statement About XMRV and CFS – showing an admirable commitment to the pursuit of the truth Dr Racaniello made an abrupt about face regarding his statement that the four papers were `probably the beginning of the end of XMRV and CFS'. His new blog "XMRV and CFS- It's Not the End' paints a very different picture andemonstrates just how difficult a subject this is. Dr. Racaniello runs a research lab – he is well versed in this field – yet this is what it took for him to alter his opinion: "I read the papers over again, and began checking XMRV sequences in Genbank. I also began an email correspondence with authors of three of the four papers, and spoke with my virology colleagues here at Columbia. As a consequence of this additional research I decided that my initial impression of the papers was incorrect, which is evident in my post entitled `Is XMRV a laboratory contaminant?" This is difficult stuff! He does believe that the new papers do highlight the dangers of contamination but they do not imply that the positive results from the WPI's or other studies were contaminated. He is fully in line with Dr. Coffin, here, who co-authored two of those papers. "Upon re-reading three of the four Retrovirology papers it became clear to me that they show that identification of XMRV can be fraught with contamination problems, but they do not imply that previously published studies are compromised by these findings. Clearly any new studies done on XMRV should keep in mind the potential for contamination from PCR kits and murine nucleic acids." Three of the papers were nothing but warnings; the Hue paper was the most substantial one and the one that bothered him the most but here, again, he was able to find reasons, some of which the WPI mentioned in their rebuttal, why the Hue paper might not apply to the WPI's findings. He seems to be indicating, oddly enough, that some XMRV isolates appear to be laboratory contaminants while others do not – was an amazing twist in an already very complex field! However, this is a twist that should be able to accounted for one would think – simply by analyzing the different strains (?). Vectors from the MoMLV virus appeared to be used in gene therapy, by the way, which is one reason they might be present in labs. The WPI, however, said the type of mice Hue described have not been used in their labs. The idea that PCR amplification could itself cause increased variability in 22Rv1 making it look like the ancestor to XMRV indicated just how complex all this is. Willow on the Phoenix Rising Forums has provided a way this could occur. "I was initially more troubled by the fourth paper by Hue and colleagues. There are four major findings in this paper (gag PCR primers are not specific for XMRV; the virus is present in 5 human tumor cell lines; two XMRV isolates are nearly identical to a virus from the human prostate cell line and also contain an insertion from the murine retrovirus MoMLV; and there is more nucleotide diversity in viral sequences from 22Rv1 cells than in all the patient XMRV sequences). The fact that two XMRV isolates seem to be laboratory contaminants – judged by the presence of MoMLV sequences – was initially unsettling until it became clear that other XMRV isolates do not have this insertion. That leaves the fourth finding – that XMRV from 22Rv1 cells appears ancestral to, and more diverse than, all the human XMRV sequences. I decided that this result was less troublesome than I had originally believed, in part because it is not clear that the differences among the 22Rv1 viruses did not arise during PCR amplification." He concluded the blog with an apology and stated that the research on XMRV and CFS must proceed and, in fact, called for it to increase. My conclusion is that these four papers point out how identification of XMRV from human specimens can be complicated by contamination, but they do not mean that previous studies were compromised. They serve as an important reminder that future experiments to identify XMRV need to be appropriately controlled to ensure that the results are not compromised by contamination. In other words, these four papers are NOT the beginning of the end of XMRV and CFS. Rather, research on the role of this virus in human disease must proceed, with large, case-controlled epidemiological studies, as suggested by others. I would like to apologize to anyone who was offended, angered, or disappointed in any way by my statement to the Chicago Tribune. It is my goal to educate the public about virology, and clearly I did not do that very well. There are at least two lessons that you can take away from this incident. First, that I make mistakes, and that I'm willing to admit it. Everyone does, including scientists. Second, if I had difficulties interpreting these papers, how would non-scientists fare? The Chicago Tribune quickly printed his retraction Respected Retrovirologist Tackles XMRV/Retrovirology `Superteam' Formed to Rebut Claims – the biggest news of the day, however, was not Dr. Racaniello's retraction but EcoClimber's statement on the Phoenix Rising Forums stating that the Retrovirology papers have prompted noted retroviriologist Dr. Dusty at the Fred Hutchinson Cancer Research Institute in Seattle, Washington to dive into his lab to investigate the contamination claims – which he does not believe will pan out and will apparently be part of a XMRV retroviral `superteam' that will rebut the claims in an organized fashion. By suggesting XMRV was a contamination – wherever it appeared – Hue's paper stepped on a lot of toes. It was Silverman, after all, who discovered XMRV in March of 2006 and since then has published 12 papers on it. Klein has been a co-author of several his papers and, of course, Dr. Ruscetti – who is very well respected in the field, was a co-author of the Science paper. These researchers may very well be doing lab work to specifically counter the Hue papers findings. Ecoclimber stated I talked to Dr. Dusty . His lab is currently in the stage in testing and experimenting and gathering the evidence to rebut their claims. He states he can refute their claims. He will be getting together with Ruscetti, Silverman, Klein, and others to post their rebuttal as a group against the negative papers. Annette Whittemore, Dr. Mikovits on Nevada Newsmakers – meanwhile Dr. Mikovits and Annette Whittemore appeared on Nevada Newsmakers to counter the claims of contamination that have been raised by a rather lazy media. Annette painted ME/CFS in broad terms – it is a complex illness that the WPI believes is infectious, involves many pathogens and affects the neuroimmune system and Dr. Mikovits noted the WPI has had interactions with researchers in countries around the world including Norway, Belgium and Spain. Dr Mikovits asserted that multiple tests are needed to detect XMRV because no single test (ie the PCR results in Retrovirology) is accurate enough. (Dr. Lipkin made a similar point in an email). Dr. Mikovits noted that they were `well aware' of the potential for contamination to skew the results, which, of course, is doubly true given co-author Dr. Ruscetti's background in mouse retroviruses and Dr. Mikovits close connection to the Ruscetti's. Annette Whittemore stated that the Retrovirology papers `do not change their findings' and that "we are moving forward in a positive way". She also noted that they were not apprised of the results before they were published – suggesting that the original authors are usually give a bit of lead time to respond to negative papers published regarding their findings. Dr. Mikovits noted that any large discovery is going to lead to `a lot of pushback' because the best science always leads to `more questions than answers' and that's what has happened. (Has it ever….The XMRV discovery pushed researchers into fields and into digging up questions that they had never asked before.) When the interviewer asked Dr. Mikovits why researchers have not followed the exact methods of the original paper her reply was very interesting. She said that researchers do what they know how to do well and that they do the advances of the last decade very well but that those kinds of techniques are just not ready to take on a new virus like this. Those new techniques have replaced the old-fashioned method of culturing, which is difficult, expensive and time consuming. (Dr. Mikovits has been saying it's not about the PCR for months). She said researchers think `if we can detect HIV using this method we should be able to detect this virus" but `that is just not the case at this point, it is too early in the discovery process". Caught in a Time Warp? – This point has confused me because they did use PCR to detect the gag sequence in the original paper and PCR. of course, is described by other commentators as something virtually any lab can do. How does this laymen make sense of all this? Perhaps PCR detection of XMRV is so difficult that just the right techniques are required to find it. It could be that small things, unbeknownst to the research community now, are able to knock XMRV off – and this is in fact what the NCI is looking reportedly at. In that case, until the PCR techniques are perfected then culturing and growing more virus and then studying it – figuring out it's little secrets – and then developing the correct PCR test would seem to make sense. I am just a laymen – no special expertise here – trying to think through these issues. Sometimes I get it right – sometimes I get it wrong; take everything printed here with that grain of salt! Unfortunately the PCR test was regarded as the main finding of the Science paper – it was what got the lion's share of attention, and PCR, as Dr Mikovits pointed out, is what researchers in this field generally do now…. Dr. Lipkin and Dr. and others are wary of PCR as the be-all and end-all of detecting viruses, and they are pursuing other means… Annette Whittemore noted all the other groups at the NIH, NCI, Cornell and University of Utah that are moving forward. When asked about politics Annette Whittemore noted that these issues are money intensive with a lot of stakeholders and some politics is inevitable….When XMRV turns out its going to cost some stakeholders a lot of money (and, of course, make money for some others). This is a long interview and I'm exhausted but it is a good interview. Dr. Mikovits and Annette Whittemore and quite poised and acquit themselves and the organization well, IMHO. Related posts: Another Kind of XMRV? Dr. Racaniello and Dr. Mikovits on XMRV The Central Issue Remains the Same – How to Find... XMRV Buzz (Dec 21st): The Retrovirology Papers Day II The Retrovirology Papers: Day Two – Not surprisingly the media... XMRV Buzz – The Buzz From Spain, Dr. Mikovits Branches Out The Buzz From Spain – Cristina Montane relayed a report... Related posts brought to you by Yet Another Related Posts Plugin. XMRV Buzz (Dec 21st): The Retrovirology Papers Day II Posted: 23 Dec 2010 01:15 PM PST The Retrovirology Papers: Day Two – Not surprisingly the media jumped on the titillating but wrong story and stated XMRV was done and that it was not the cause of ME/CFS. XMRV certainly did take a hit, yesterday, but several important names, particularly Dr. Coffin – who was a co-author of two of the papers , and has been doing his own research on how to tell XMRV apart from a contaminant, refused to fold XMRV's tent stating that the arguments against XMRV were subtle and indirect and that none of them directly indicated the WPI had inadvertently come with a contaminant. Indeed three of the four papers demonstrated that they had found a contaminant but not that the WPI did. The paper indicated that one test for contamination that neither the WPI or the Lo lab used(?) was more sensitive than the mtDNA test that the WPI reportedly used. But it was only MORE sensitive; even if the WPI or Lo study mischaracterized some contaminated samples there was nothing in the report to suggest that they mischaracterized ALL of them – something that doesn't appear to be even remotely tenable. Similarly, the Oakes paper described a situation where tests for contamination revealed that yes, contamination was present. It's certainly a warning but both the WPI and the Alter studies tested for contamination and they did not find it. The Hue paper - was the only potential body blow to XMRV of the four. Dr. Hue's phylogenetic analysis suggested that XMRV was not derived from a wild mouse but came from a cell line grown in a laboratory. Hue's argument was that if XMRV was a human pathogen that is widespread in the population – as studies suggest it is – then it would have, like HIV, and other viruses picked up a great deal of variability. But Hue found that XMRV was actually less variable than the 22RV1 cell line his analyses suggested it was derived from. Hue, however, only used two full length XMRV genomes for ME/CFS patients in his analysis. Whether or not he needed more is unclear – he also used 1 representative of other mouse viruses in his analysis but it does make one wonder about the many unsequenced strains sitting in the WPI's labs. Whether including them might possibly have altered his results is a question for a population geneticist…. Hue also showed that the standard PCR test for XMRV was not as specific as had been originally thought and that it can misidentifies endogenous MLV sequences from some mouse strains as being XMRV. The misidentification is something of chimera for the WPI; the fact that they could grow viruses indicated that they did find XMRV. The WPI countered with the fact that a) they can grow the virus – so the PCR results were not simply the result of some mouse DNA getting into their samples and that their antibody test indicated an immune response had been created to a virus, not a contaminant. They did not reply to concerns about Hue's phylogenetic analysis. Dr. Racaniello Does a Partial Turnaround – To read that Dr. Racaniello said that XMRV's course in CFS was probably over was rough, considering that he has been considered to be an objective source. Over night, however, Dr. Racaniello reconsidered his opinion and the next day concluded that, while his concerns remained, he had overstated "I do not believe that the four Retrovirology papers prove that XMRV is not involved in human disease." Related posts: Retrovirology Publishes Five Articles on XMRV and Contamination Retrovirology Journal Publishes Four Studies on XMRV and Contamination Retrovirology... XMRV Buzz Nov 21st – Mice, Dr. Enlander and being `Undefeated' The XMRV Buzz -short takes on the world of XMRV... `Altered' Reality: the XMRV Papers Disappearing Trick Amy Dockser Marcus at the Wall Street Journal has become... Related posts brought to you by Yet Another Related Posts Plugin. You are subscribed to email updates from Bringing the Heat: An ME/CFS Blog Email delivery powered by Google Google Inc., 20 West Kinzie, Chicago IL USA 60610 Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.